Список литературы к Главе 18

1. Smolej L. et al. Low­dose fludarabine and cyclophosphamide combined with rituximab is a safe and effective treatment option for elderly and comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: preliminary results of project Q­lite, by the Czech CLL Study Group // Clin. Lymphoma Myeloma Leuk. 2011. Vol. 11. P. S261.

2. Mulligan S.P. et al. A randomised dose de­escalation safety study of oral fludarabine, ±oral cyclophosphamide and intravenous rituximab (OFOCIR) as first­line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years: final analysis of response and toxicity // Blood. 2014. Vol. 124. P. 3325.

3. Nikitin E. et al. Randomised comparison of FCRLite And ClbR (chlorambucil plus rituximab) regimens in elderly patients with chronic lymphocytic leukemia // Hematologica. 2013. Vol. 98, suppl. 1. P. 473. Abstr. NS1147.

4. Foon K.A. et al. Long­term results of chemoimmunotherapy with low­dose fludarabine, cyclophosphamide and high­dose rituximab as initial treatment for patients with chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 13. P. 3184–3185. DOI: https://doi.org/10.1182/blood­2012­01­408047

5. Shvidel L. et al. Conventional dose fludarabine­based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia // Leuk. Lymphoma. 2003. Vol. 44, N 11. P. 1947–1950. DOI: https://doi.org/10.1080/1042819031000110991

6. Marotta G. et al. Low­dose fludarabine and cyclophosphamide in elderly patients with B­cell chronic lymphocytic leukemia refractory to conventional therapy // Haematologica. 2000. Vol. 85, N 12. P. 1268–1270.

7. Abel G.A. The real world: CLL // Blood. 2011. Vol. 117, N 13. P. 3481–3482. DOI: https://doi.org/10.1182/blood­2011­01­328625 PMID: 21454464.

8. Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms // Blood. 2016. Vol. 127, N 20. P. 2375–2390. DOI: https://doi.org/10.1182/blood­2016­01­643569 Epub 2016 Mar 15. PMID: 26980727; PMCID: PMC4874220.

9. Sant M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project [published correction appears in Blood. 2011. Vol. 117, N 12. P. 3477] // Blood. 2010. Vol. 116, N 19. P. 3724–3734. DOI: https://doi.org/10.1182/blood­2010­05­282632

10. Dores G.M. et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology // Br. J. Haematol. 2007. Vol. 139, N 5. P. 809–819. DOI: https://doi.org/10.1111/j.1365­2141.2007.06856.x

11. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва : МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.

12. Kipps T.J. et al. Chronic lymphocytic leukaemia // Nat. Rev. Dis. Primers. 2017. Vol. 3. Article ID 16096. DOI: https://doi.org/10.1038/nrdp.2016.96 Epub 2017 Jan 19.

13. World Health Organization. World Health Statistics 2016: Monitoring Health for the SDGs Annex B: Tables of Health Statistics by Country. WHO Region and Globally, 2016.

14. National Cancer Institute Surveillance, Epidemiology, and End Results. Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia (CLL), 2020. URL: https://seer.cancer.gov/statfacts/html/clyl.html

15. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760. DOI: https://doi.org/10.1182/blood­2017­09­806398

16. Weide R. et al. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017 // Leuk. Lymphoma. 2020. Vol. 61, N 3. P. 557–566. DOI: https://doi.org/10.1080/10428194.2019.1680840

17. Rai K.R. et al. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46, N 2. P. 219–234. DOI: https://doi.org/10.1182/blood­2016­08­737650

18. Binet J.L. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206. DOI: https://doi.org/10.1002/1097­0142(19810701)48:1<198::aid­ cncr2820480131>3.0.co;2­v

19. International CLL­IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL­IPI): a meta­analysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790. DOI: https://doi.org/10.1016/S1470­2045(16)30029­8

20. Rai K.R., Han T. Prognostic factors and clinical staging in chronic lymphocytic leukemia // Hematol. Oncol. Clin. North Am. 1990. Vol. 4, N 2. P. 447–456.

21. Mato A. et al. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites // Blood Adv. 2020. Vol. 4, N 7. P. 1407–1418. DOI: https://doi.org/10.1182/bloodadvances.2019001145 PMID: 32271900; PMCID: PMC7160291.

22. Stilgenbauer S. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254. DOI: https://doi.org/10.1182/blood­2014­01­546150

23. Ballman K.V. Biomarker: predictive or prognostic? // J. Clin. Oncol. 2015. Vol. 33, N 33. P. 3968–3971. DOI: https://doi.org/10.1200/ JCO.2015.63.3651

24. Gaidano G., Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment // Hematology Am. Soc. Hematol. Educ. Program. 2017. Vol. 2017, N 1. P. 329–337. DOI: https://doi.org/10.1182/ asheducation­2017.1.329

25. Pal K. et al. GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data // Bioinformatics. 2017. Vol. 33, N 23. P. 3802–3804. DOI: https://doi.org/10.1093/bioinformatics/btx423

26. Döhner H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 26. P. 1910–1916. DOI: https://doi.org/10.1056/NEJM200012283432602

27. Catherwood M.A. et al. Relevance of TP53 for CLL diagnostics // J. Clin. Pathol. 2019. Vol. 72, N 5. P. 343–346. DOI: https://doi.org/10.1136/jclinpath­2018­205622 Epub 2019 Feb 2. PMID: 30712002.

28. Baliakas P. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact // Blood. 2019. Vol. 133, N 11. P. 1205–1216. DOI: https://doi.org/10.1182/blood­2018­09­873083

29. Kröber A. et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia // Blood. 2002. Vol. 100, N 4. P. 1410–1416.

30. Zenz T. et al. From pathogenesis to treatment of chronic lymphocytic leukaemia // Nat. Rev. Cancer. 2010. Vol. 10, N 1. P. 37–50. DOI: https://doi.org/10.1038/nrc2764

31. Ten Hacken E. et al. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia // Leukemia. 2019. Vol. 33, N 2. P. 287–298. DOI: https://doi.org/10.1038/s41375­018­0303­x

32. Hamblin T.J. et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1848–1854.

33. Damle R.N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 6. P. 1840–1847.

34. Thompson P.A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long­term disease­free survival in IGHV­mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309. DOI: https://doi.org/10.1182/blood­2015­09­667675

35. Agathangelidis A. et al. Higher­order connections between stereotyped subsets: implications for improved patient classification in CLL // Blood. 2021. Vol. 137, N 10. P. 1365–1376. DOI: https://doi.org/10.1182/blood.2020007039 PMID: 32992344.

36. Baliakas P. et al. European Research Initiative on CLL (ERIC). Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia // Haematologica. 2019. Vol. 104, N 2. P. 360–369. DOI: https://doi.org/10.3324/haematol.2018.195032 Epub 2018 Sep 27. PMID: 30262567; PMCID: PMC6355487.

37. Dartigeas C. et al.; CLL 2007 SA Investigators; French Innovative Leukemia Organization (FILO). Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open­label, randomised phase 3 study // Lancet Haematol. 2018. Vol. 5, N 2. P. e82–e94. DOI: https://doi.org/10.1016/S2352­3026(17)30235­1 Epub 2017 Dec 20. PMID: 29275118.

38. Tertian G. et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia // Hematol. Cell Ther. 1996. Vol. 38, N 4. P. 359–360. DOI: https://doi.org/10.1007/s00282­996­0359­3

39. Longo G. et al. Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia // Eur. J. Haematol. 1997. Vol. 59, N 2. P. 124–125. DOI: https://doi.org/10.1111/j.1600­0609.1997.tb00737.x

40. Taha H.M., Narasihman P., Venkatesh L., Cawley M., Kaplan B. Fludarabine­related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders // Am. J. Hematol. 1998. Vol. 59, N 4. P. 316. DOI: https://doi.org/10.1002/(sici)1096­8652(199812)59:4<316::aid­ajh8>3.0.co;2­g

41. Gonzalez H. et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine // Hematol. Cell Ther. 1998. Vol. 40, N 3. P. 113–118.

42. Martell R.E. et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CAL­GB (9011) coordinated intergroup study // Cancer Chemother. Pharmacol. 2002. Vol. 50, N 1. P. 37–45. DOI: https://doi.org/10.1007/s00280­002­0443­5

43. Hersh M.R. et al. Pharmacokinetic study of fludarabine phosphate (NSC 312887) // Cancer Chemother. Pharmacol. 1986. Vol. 17. P. 277–280.

44. Lichtman S.M. et al. Development of a fludarabine phosphate (FAMP) dosing formula in patients with renal insufficiency based on a pharmacokinetic (PK) study in patients with and without renal impairment // Proc. Am. Soc. Clin. Oncol. 1998. Vol. 17. Abstr. 845.

45. Leporrier M. et al. Pure red­cell aplasia with fludarabine for chronic lymphocytic leukaemia // Lancet. 1993. Vol. 342, N 8870. P. 555.

46. Elefante A., Czuczman M.S. Bendamustine for the treatment of indolent non­Hodgkin’s lymphoma and chronic lymphocytic leukemia // Am. J. Health Syst. Pharm. 2010. Vol. 67, N 9. P. 713–723. DOI: https://doi.org/10.2146/ ajhp090328

47. Cuneo A. et al. Appropriate use of bendamustine in first­line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group // Leuk. Res. 2014. Vol. 38, N 11. P. 1269–1277. DOI: https://doi.org/10.1016/j.leukres.2014.06.017

48. Eichhorst B. et al. First­line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open­label, randomised, phase 3, non­inferiority trial // Lancet Oncol. 2016. Vol. 17, N 7. P. 928–942. DOI: https://doi.org/10.1016/S1470­2045(16)30051­1

49. Ahn I.E. et al. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia // Blood Adv. 2017. Vol. 1, N 25. P. 2433–2443. DOI: https://doi.org/10.1182/bloodadvances.2017011262 Epub 2017 Nov 28.